The synergy between the KEAP1/NRF2 and PI3K pathways drives NSCLC with an altered immune microenvironment and achieves tumour regression through suppression of immune checkpoint [58]. The gene discussed is NFE2L2; the disease is non-small cell lung carcinoma.